Humacyte (NASDAQ:HUMA) Trading Down 5.2%

Shares of Humacyte, Inc. (NASDAQ:HUMA) were down 5.2% on Thursday . The stock traded as low as $4.72 and last traded at $4.74. Approximately 1,073,898 shares were traded during mid-day trading, a decline of 35% from the average daily volume of 1,660,652 shares. The stock had previously closed at $5.00.

Wall Street Analyst Weigh In

Several research analysts have weighed in on HUMA shares. Piper Sandler restated a “neutral” rating and issued a $4.00 price target on shares of Humacyte in a research note on Tuesday, March 26th. Benchmark restated a “buy” rating and issued a $15.00 price target on shares of Humacyte in a research note on Friday, May 24th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $7.00 target price on shares of Humacyte in a research report on Monday, April 1st.

Humacyte Stock Up 2.1 %

The business has a 50-day moving average price of $5.89 and a 200 day moving average price of $4.17. The company has a current ratio of 8.37, a quick ratio of 8.37 and a debt-to-equity ratio of 0.61.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings results on Friday, May 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). On average, sell-side analysts expect that Humacyte, Inc. will post -0.95 EPS for the current year.

Insiders Place Their Bets

In other Humacyte news, Director Brady W. Dougan sold 271,518 shares of the stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $7.30, for a total value of $1,982,081.40. Following the sale, the director now owns 4,559,140 shares in the company, valued at $33,281,722. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, Director Brady W. Dougan sold 271,518 shares of the firm’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $7.30, for a total transaction of $1,982,081.40. Following the transaction, the director now owns 4,559,140 shares in the company, valued at $33,281,722. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Gordon M. Binder acquired 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 15th. The shares were bought at an average cost of $6.78 per share, for a total transaction of $339,000.00. Following the transaction, the director now owns 160,000 shares of the company’s stock, valued at $1,084,800. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 54,412 shares of company stock worth $369,107 and have sold 1,628,820 shares worth $12,464,121. Insiders own 23.10% of the company’s stock.

Institutional Investors Weigh In On Humacyte

A number of institutional investors have recently added to or reduced their stakes in HUMA. Tower Research Capital LLC TRC boosted its holdings in Humacyte by 261.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,989 shares of the company’s stock worth $26,000 after acquiring an additional 6,504 shares in the last quarter. Whittier Trust Co. of Nevada Inc. acquired a new stake in shares of Humacyte during the fourth quarter worth about $28,000. Victory Capital Management Inc. acquired a new stake in shares of Humacyte during the fourth quarter worth about $29,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Humacyte by 350.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,986 shares of the company’s stock worth $34,000 after purchasing an additional 9,325 shares during the period. Finally, Kovitz Investment Group Partners LLC acquired a new stake in shares of Humacyte during the fourth quarter worth about $35,000. Institutional investors own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.